American Association for Cancer Research

AACR CANCER POLICY MONITOR

CPM

                                                                                                          APRIL 2009

HAMBURG SELECTED TO LEAD FDA

 

Appointee still awaiting senate confirmation

Margaret Hamburg, M.D., has been nominated to become the next commissioner of the Food and Drug Administration (FDA).

Hamburg is a former commissioner of health for New York City and has also served as the assistant director of the National Institute of Allergy and Infectious Disease of the National Institutes of Health. When announcing her appointment during a weekly address on March 14, President Obama praised her reputation for integrity and record of achievement in assuring the safety and security of Americans.

Working with Hamburg at the FDA will be Joshua Sharfstein, M.D., who has been named deputy commissioner. Since 2005, Sharfstein has served as the head of the Baltimore City Department of Health in Maryland. He is a pediatrician and a former health policy aide to Rep. Henry Waxman (D-Calif.), now chair of the House Energy and Commerce Committee, which holds jurisdiction over health issues and the pharmaceutical industry.

Hamburg still awaits official confirmation by the U.S. Senate; no hearing date has yet been scheduled. Sharfstein, whose position does not require Senate confirmation, is currently serving as the agency's acting commissioner until Hamburg is confirmed.  

Links:

In the News:

Read More from the April Edition of the AACR Cancer Policy Monitor:

Top